Back to search
FDAFDA · Food and drugs·Recall number D-0929-2017

Blephamide (sulfacetamide sodium and prednisolone acetate ophthalmic ointment, USP) 10%/0.2% sterile, 3.5 g tube, RX only, Manufactured by Allergan, Irvine, California, 92612, U.S.A., NDC: 0023-0313-04.

Published July 5, 2017 · Recall initiated: May 1, 2017

Summary

FDA records drug Class II recall D-0929-2017, published July 5, 2017 and initiated May 1, 2017. Recalling firm: Allergan Sales, LLC; Status: Terminated; Reported quantity: 648 units; Lot: Lot: 93802, EXP NOV 2019. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Impurities/Degradation Specifications: stability testing results did not meet the specification for impurities.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Allergan Sales, LLC
Distributor
Nationwide in the US
Lot
Lot: 93802, EXP NOV 2019
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Blephamide (sulfacetamide sodium and prednisolone acetate ophthalmic ointment, USP) 10%/0.2% sterile, 3.5 g tube, RX only, Manufactured by Allergan, Irvine, California, 92612, U.S.A., NDC: 0023-0313-04. recalled?

Yes. FDA published recall D-0929-2017 on July 5, 2017. Reported hazard: Failed Impurities/Degradation Specifications: stability testing results did not meet the specification for impurities.

What should I do if I have this product?

Voluntary: Firm initiated · Letter